Department of Otolaryngology-Head and Neck Surgery, Head and Neck Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Am J Otolaryngol. 2012 Jan-Feb;33(1):98-103. doi: 10.1016/j.amjoto.2011.02.005. Epub 2011 Jun 22.
T1 and T2 tonsillar squamous cell cancer with limited neck disease can be managed with single-modality radiation or surgery. Over 11 years, 17 patients underwent radical tonsillectomies; and 33 patients underwent radiation-based treatments for T1 and T2 and N0 to N2a tonsil cancer. Patients were intended to receive single-modality treatment based on presentation; however, some ultimately received adjuvant treatments.
A retrospective chart review to compare overall survival (OS), disease-specific survival (DSS), and locoregional control (LRC) between the groups was used.
In surgical group, of 17 patients, 11 underwent surgery alone, 3 underwent surgery and radiation, and 3 underwent surgery with concurrent chemoradiation. Five-year OS for the surgical and radiation groups was 93% and 72%, respectively (no significance achieved). Five-year DSS rates (93% and 80%) and LRC (69% and 89%) similarly did not yield any significant difference.
Surgery remains a viable option in the management of T1 and T2 tonsillar cancers with comparable LRC, OS, and DSS.
局限于颈部的 T1 和 T2 扁桃体鳞状细胞癌可以通过单一模式的放射治疗或手术来治疗。11 年来，17 名患者接受了根治性扁桃体切除术；33 名患者接受了 T1、T2 和 N0 至 N2a 扁桃体癌的基于放射的治疗。根据表现，患者计划接受单一模式治疗；然而，一些患者最终接受了辅助治疗。
使用回顾性图表审查来比较两组之间的总生存率（OS）、疾病特异性生存率（DSS）和局部区域控制率（LRC）。
在手术组中，17 名患者中，11 名仅接受手术治疗，3 名接受手术加放疗，3 名接受手术加同期放化疗。手术组和放疗组的 5 年 OS 分别为 93%和 72%（无显著差异）。5 年 DSS 率（93%和 80%）和 LRC（69%和 89%）也没有显著差异。
对于 T1 和 T2 扁桃体癌，手术仍然是一种可行的治疗选择，具有可比的局部区域控制率、总生存率和疾病特异性生存率。
